Synbio International, Inc.
No SEC Form 4 filings for $SYIN in the last 30 days.
See all $SYIN insider activity →Synbio International (SYIN) announced a dual growth strategy: launching Healing Force nutraceuticals in the U.S. and Canada, and advancing FacialDx’s NIMS mental health screening through an Australian feasibility study, targeting non-dilutive funding.
Synbio International (SYIN) signed an exclusive licensing deal with MD PHD Wellness for its anti-anxiety nutraceutical, to be sold under Synbio’s Healing Force™ brand. The agreement accelerates Synbio’s revenue path by leveraging MD PHD’s product expertise and Synbio’s marketing capabilities. Profits will be shared after cost recovery. Synbio aims to expand its wellness portfolio and generate near-term revenue while advancing its AI-driven healthcare technologies.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SYIN (Synbio International, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SYIN coverage spans financial news and corporate actions.
The announcement may generate modest buying interest as early commercial activity and a funded clinical pathway could de‑risk the company's long‑term AI health‑tech bet.
The deal could boost short‑term sales and improve cash flow, but financial impact depends on product performance and market adoption.
AlphAI scores every news story that mentions SYIN with an AI model for sentiment and relevance, and aggregates insider trades from Synbio International, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Synbio International (SYIN) announced a dual growth strategy: launching Healing Force nutraceuticals in the U.S. and Canada, and advancing FacialDx’s NIMS mental health screening through an Australian feasibility study, targeting non-dilutive funding.
1 min readSynbio International (SYIN) signed an exclusive licensing deal with MD PHD Wellness for its anti-anxiety nutraceutical, to be sold under Synbio’s Healing Force™ brand. The agreement accelerates Synbio’s revenue path by leveraging MD PHD’s product expertise and Synbio’s marketing capabilities. Profits will be shared after cost recovery. Synbio aims to expand its wellness portfolio and generate near-term revenue while advancing its AI-driven healthcare technologies.
1 min read
